G‐protein‐coupled bile acid receptor plays a key role in bile acid metabolism and fasting‐induced hepatic steatosis in mice

Ajay C. Donepudi, Shannon Boehme, Feng Li, John Y.L. Chiang – 28 June 2016 – Bile acids are signaling molecules that play a critical role in regulation of hepatic metabolic homeostasis by activating nuclear farnesoid X receptor (Fxr) and membrane G‐protein‐coupled receptor (Takeda G‐protein‐coupled receptor 5; Tgr5). The role of FXR in regulation of bile acid synthesis and hepatic metabolism has been studied extensively. However, the role of TGR5 in hepatic metabolism has not been explored.

Inhibition of mast cell‐secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2−/− mice

Hannah Jones, Laura Hargrove, Lindsey Kennedy, Fanyin Meng, Allyson Graf‐Eaton, Jennifer Owens, Gianfranco Alpini, Christopher Johnson, Francesca Bernuzzi, Jennifer Demieville, Sharon DeMorrow, Pietro Invernizzi, Heather Francis – 28 June 2016 – Hepatic fibrosis is marked by activation of hepatic stellate cells (HSCs). Cholestatic injury precedes liver fibrosis, and cholangiocytes interact with HSCs promoting fibrosis. Mast cells (MCs) infiltrate following liver injury and release histamine, increasing biliary proliferation.

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud‐Ratti, Tarik Asselah – 28 June 2016 – Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon‐alpha (Peg‐IFN‐α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.

Subscribe to